These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2180614)

  • 1. Increased renal clearance of cefsulodin due to higher glomerular filtration rate in cystic fibrosis.
    Hedman A; Alván G; Strandvik B; Arvidsson A
    Clin Pharmacokinet; 1990 Feb; 18(2):168-75. PubMed ID: 2180614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of the glomerular filtration rate on renal clearance of ceftazidime in cystic fibrosis.
    Hedman A; Adan-Abdi Y; Alvan G; Strandvik B; Arvidsson A
    Clin Pharmacokinet; 1988 Jul; 15(1):57-65. PubMed ID: 3042246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Difference in renal handling of cefsulodin between patients with cystic fibrosis and normal subjects.
    Arvidsson A; Alván G; Strandvik B
    Acta Paediatr Scand; 1983 Mar; 72(2):293-4. PubMed ID: 6837304
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessment of glomerular filtration rate and effective renal plasma flow in cystic fibrosis.
    Spino M; Chai RP; Isles AF; Balfe JW; Brown RG; Thiessen JJ; MacLeod SM
    J Pediatr; 1985 Jul; 107(1):64-70. PubMed ID: 3891948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reassessment of the single intravenous injection method with inulin for measurement of the glomerular filtration rate in man.
    Prescott LF; Freestone S; McAuslane JA
    Clin Sci (Lond); 1991 Feb; 80(2):167-76. PubMed ID: 1848170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disposition of drugs in cystic fibrosis. IV. Mechanisms for enhanced renal clearance of ticarcillin.
    Wang JP; Unadkat JD; al-Habet SM; O'Sullivan TA; Williams-Warren J; Smith AL; Ramsey B
    Clin Pharmacol Ther; 1993 Sep; 54(3):293-302. PubMed ID: 8375124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal function and renotropic effects of secretin in cystic fibrosis.
    Windstetter D; Schaefer F; Schärer K; Reiter K; Eife R; Harms HK; Bertele-Harms R; Fiedler F; Tsui LC; Reitmeir P; Horster M; Hadorn HB
    Eur J Med Res; 1997 Oct; 2(10):431-6. PubMed ID: 9348270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of inulin clearance by bolus intravenous injection in healthy subjects and ascitic patients: equivalence of systemic and renal clearances as glomerular filtration markers.
    Orlando R; Floreani M; Padrini R; Palatini P
    Br J Clin Pharmacol; 1998 Dec; 46(6):605-9. PubMed ID: 9862251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study.
    Levy J; Smith AL; Koup JR; Williams-Warren J; Ramsey B
    J Pediatr; 1984 Jul; 105(1):117-24. PubMed ID: 6376743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of four methods for measuring glomerular filtration rate by inulin clearance in healthy individuals and patients with renal failure].
    Hernández Ocampo J; Torres Rosales A; Rodríguez Castellanos F
    Nefrologia; 2010; 30(3):324-30. PubMed ID: 20414326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects.
    Golper TA; Noonan HM; Elzinga L; Gilbert D; Brummett R; Anderson JL; Bennett WM
    Clin Pharmacol Ther; 1988 May; 43(5):565-70. PubMed ID: 3365918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefsulodin kinetics in renal impairment.
    Gibson TP; Granneman GR; Kallal JE; Sennello LT
    Clin Pharmacol Ther; 1982 May; 31(5):602-8. PubMed ID: 7075110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-dose pharmacokinetics of cefsulodin in patients with cystic fibrosis.
    Reed MD; Stern RC; Yamashita TS; Ackers I; Myers CM; Blumer JL
    Antimicrob Agents Chemother; 1984 May; 25(5):579-81. PubMed ID: 6732226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics of cefsulodin in patients with renal impairment.
    Gibson TP; Granneman GR; Kallal JE; Sennello LT
    Rev Infect Dis; 1984; 6 Suppl 3():S689-97. PubMed ID: 6571338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport?
    Susanto M; Benet LZ
    Pharm Res; 2002 Apr; 19(4):457-62. PubMed ID: 12033380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased renal clearance of sodium in cystic fibrosis.
    Stenvinkel P; Hjelte L; Alván G; Hedman A; Hultman E; Strandvik B
    Acta Paediatr Scand; 1991 Feb; 80(2):194-8. PubMed ID: 2035310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis.
    Beringer PM; Kriengkauykiat J; Zhang X; Hidayat L; Liu S; Louie S; Synold T; Burckart GJ; Rao PA; Shapiro B; Gill M
    Pharmacotherapy; 2008 Jul; 28(7):883-94. PubMed ID: 18576903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma clearance rates and renal clearance of 3H-labeled cyclic AMP and 3H-labeled cyclic GMP in the dog.
    Blonde L; Wehmann RE; Steiner AL
    J Clin Invest; 1974 Jan; 53(1):163-72. PubMed ID: 4357610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacology of antibiotics and other drugs in cystic fibrosis.
    Prandota J
    Drugs; 1988 May; 35(5):542-78. PubMed ID: 3293970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism of proinsulin, insulin, and C-peptide in the rat.
    Katz AI; Rubenstein AH
    J Clin Invest; 1973 May; 52(5):1113-21. PubMed ID: 4700486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.